AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02167126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity.
Study NCT00387205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
Study NCT02921230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral stenting
Description: stent implantation during the index procedure
Study NCT02921230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral stenting
Description: stent implantation during the index procedure
Study NCT03477110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT03477110 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03477110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A Device
Description: Undergo tumor treatment fields therapy using NovoTTF-200A device
Study NCT03477110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Undergo tumor treatment fields therapy using NovoTTF-200A device
Study NCT02943382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fingerprick autologous blood (FAB)
Description: Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
Study NCT04470817 — intervention group
Intervention type: DRUG
Intervention: Azilsartan Medoxomil
Description: Azilsartan Medoxomil
Study NCT03365856 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: as clinical practice
Study NCT04438915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effect of Obesity on incidence of Postoperative cognitive in Gynecological Day- Day- case surgery
Description: The effect of obesity on the incidence of postoperative cognitive dysfunction in Gynecological day-case surgery
Study NCT03744117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care consultation
Description: A palliative care consultation will occur via telemedicine with patients receiving maintenance dialysis.
Study NCT03148054 — intervention group
Intervention type: DEVICE
Intervention: Computer Tomography and Endoscopy
Description: Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).~Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system.
Study NCT02397889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
Study NCT02397889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
Study NCT01250951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study NCT03001362 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical external beam radiotherapy
Description: pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.
Study NCT02258295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intragel
Description: Intragel has an average molecular weight of 800-1200 kDaltons.
Study NCT02258295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline
Study NCT02167126 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio Taping
Description: using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity.
Study NCT02167126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Tape
Description: Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella.
Study NCT02167126 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tape
Description: Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella.
Study NCT00852228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV cetuximab
Description: Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
Study NCT00852228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI chronomodulated chemotherapy
Description: Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks.
Study NCT00852228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI conventional chemotherapy
Description: Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks.
Study NCT01674569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82 oral
Description: X-82 oral for 24 weeks or until unacceptable toxicity develops
Study NCT02834312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
Study NCT01651052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart Valve Surgery
Description: Implant of an aortic valve, Model 11000
Study NCT02686762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan (5 mg)
Description: Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
Study NCT02686762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan (50 mg)
Description: Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
Study NCT02686762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
Study NCT05303948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy / Direct Laryngoscopy
Description: First pass success analysis
Study NCT05124496 — intervention group
Intervention type: DEVICE
Intervention: Screening Device
Description: Screening device comparing Rt-PCR positive and negative results to HyperDetector results
Study NCT00374049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MUC_1
Description: Pretreatment with Poly-ICLC alone week 1 \&2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
Study NCT01674569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab (Lucentis)
Description: Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
Study NCT01894347 — intervention group
Intervention type: OTHER
Intervention: TDM, Monitoring of Neuro-and Nephropathology
Description: Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
Study NCT01273701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial intervention
Description: The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1.
Study NCT02466087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mg Cl
Description: Four supplements a day for 6 weeks.
Study NCT02564016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Infusion
Description: Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
Study NCT02564016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capped Epidural
Description: epidural will be capped with no saline infusion.
Study NCT01273701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1.
Study NCT01273701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone reminding
Description: Subjects in TSTSU-T group will receive addition telephone reminding one day before each visit. Each call will be no longer than five minutes. On the telephone, brief motivation enhancement may be conducted.
Study NCT04363762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based multimodal pain program
Description: A guided internet-based multimodal pain program for chronic TMD pain
Study NCT04363762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal splint
Description: Occlusal splint, standard
Study NCT04223362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based physical activity programme
Description: After completing a pulmonary rehabilitation programme, participants will enrol a 6-months personalised community-based physical activity programme, which will include 2 sessions/week, with the aerobic training being the cornerstone. Patients will receive the PICk UP manual and a diary to register their physical activities. During the 1st month the physiotherapist will guide patients through 4 types of outdoors and indoors physical activities. Patients will then be asked to choose and commit to 1 or 2 activities, according to their preferences, which they shall integrate for another 5 months. During this period, the support provided by physiotherapist will decrease over time.
Study NCT04223362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.
Study NCT04223362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Patients will receive the same pulmonary rehabilitation programme as the experimental group, i.e., exercise training twice a week and education and psychosocial support once every other week, which integrates physical activity recommendations.
Study NCT03014687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
Study NCT03014687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
Description: Oral antibiotics (cefdinir \[Omnicef®\] 300 mg PO BID or trimethoprim/sulfamethoxazole \[Bactrim DS™\] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
Study NCT01766167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: Low
Study NCT01766167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: Middle
Study NCT01766167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: High
Study NCT01766167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: Multiple
Study NCT02890693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interdisciplinary lifestyle and psychosocial intervention
Description: The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
Study NCT01588704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Bevacizumab
Description: Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
Study NCT04241796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Cancer Early Detection Test
Description: Blood collection and multi-cancer early detection testing with return of results.
Study NCT03780309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Self-Monitoring
Description: Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
Study NCT03780309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Self-Monitoring
Description: Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
Study NCT03780309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Pressure Self-Monitoring
Description: Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
Study NCT00454662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan medoxomil / amlodipine or azelnidipine
Description: AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
Study NCT00454662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan medoxomil / low dose thiazide type drug
Description: AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
Study NCT02601703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Ointment 0.1%
Description: apply thin layer of ointment to affected area
Study NCT02601703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic® ointment, 0.1%
Description: apply thin layer of ointment to affected area
Study NCT02601703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Tacrolimus Ointment
Description: apply thin layer of ointment to affected area
Study NCT01801319 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Libra Deep Brain Stimulation System
Study NCT01801319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Libra Deep Brain Stimulation System
Study NCT02837380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
Study NCT02837380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI/UMEC
Description: VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
Study NCT02282527 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Liquid Alpha₁-PI
Description: Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
Study NCT02282527 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prolastin-C
Description: Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
Study NCT03735771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.25% bupivacaine plus fentanyl 8 mcg/ml
Study NCT04097899 — intervention group
Intervention type: OTHER
Intervention: implementation of antimicrobial stewardship comprehensive care bundle program on ventilator associated pneumonia patients
Description: Construction of a comprehensive care bundle educational program. This program consisted of many elements: Antimicrobial stewardship programs, VAP bundles and infection control policy implementation and the investigators studied the impact of this program on:~* Antibiotics cost.~* Appropriates of antibiotic use (initiation, duration \& time of discontinuation).~* Rate of resistance~* Clinical outcome, infection rate \&length of stay.
Study NCT04782999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Standard test of glucose tolerance with ingestion of 75 g glucose followed by blood sampling.
Study NCT04782999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemic clamp with infusion of saline, GLP-1 or GIP
Description: Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.~Primed co-infusion of either:~* Saline~* GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)~* GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min).
Study NCT03031756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glycine powder air-polishing (Air-Flows)Perio Powder
Study NCT03031756 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)
Study NCT03031756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)